In the last trading session, 1.7 million shares of the Standard BioTools Inc (NASDAQ:LAB) were traded, and its beta was 1.56. Most recently the company’s share price was $2.02, and it changed around $0.09 or 4.66% from the last close, which brings the market valuation of the company to $751.96M. LAB currently trades at a discount to its 52-week high of $3.04, offering almost -50.5% off that amount. The share price’s 52-week low was $1.21, which indicates that the current value has risen by an impressive 40.1% since then. We note from Standard BioTools Inc’s average daily trading volume that its 10-day average is 1.48 million shares, with the 3-month average coming to 1.80 million.
Standard BioTools Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 3 analysts rate the stock as a Sell; another 0 rate it as Overweight. Among the rest, 0 recommended LAB as a Hold, whereas 3 deemed it a Buy, and 0 rated it as Underweight. Standard BioTools Inc is expected to report earnings per share of -0.03 for the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Standard BioTools Inc (NASDAQ:LAB) trade information
Instantly LAB has showed a green trend with a performance of 4.66% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 2.0600 on recent trading dayincreased the stock’s daily price by 1.94%. The company’s shares are currently down -8.60% year-to-date, but still up 10.38% over the last five days. On the other hand, Standard BioTools Inc (NASDAQ:LAB) is -6.05% down in the 30-day period. We can see from the shorts that 13.77 million shares have been sold at a short interest cover period of 5.3 day(s).
The consensus price target as assigned by Wall Street analysts is $3.25, which translates to bulls needing to increase their stock price by 37.85% from its current value. Analyst projections state that LAB is forecast to be at a low of $3.25 and a high of $3.25.
Standard BioTools Inc (LAB) estimates and forecasts
Standard BioTools Inc share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -14.41 percent over the past six months and at a 53.66% annual growth rate that is well above the industry average of 24.50%. The year-over-year growth rate is expected to be 60.99%, up from the previous year.
Consensus estimates provided by 3 financial analysts predict the company will bring in an average of 43.03M in revenue for the current quarter. 2 analysts expect Standard BioTools Inc to make 45.6M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 28.19M and 45.54M respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 52.67%. Forecasts for the next quarter put sales growth at 0.13%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 8.72%. Standard BioTools Inc earnings are expected to increase by 62.06% in 2024, but the outlook is negative -8.06% per year for the next five years.
LAB Dividends
Standard BioTools Inc’s next quarterly earnings report is expected to be released in January.
Standard BioTools Inc (NASDAQ:LAB)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 1.93% of Standard BioTools Inc shares, and 73.33% of them are in the hands of institutional investors. The stock currently has a share float of 74.78%. Standard BioTools Inc stock is held by 189.0 institutions, with CASDIN CAPITAL, LLC being the largest institutional investor. By 2024-06-30, it held 17.1782% of the shares, which is about 63.96 million shares worth $113.21 million.
VIKING GLOBAL INVESTORS LP, with 15.7524% or 58.65 million shares worth $103.81 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
